Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewBIOSPAIN 2026 and the UK: Connecting two leading biotech ecosystems to drive innovation an...
The United Kingdom will be the Guest Nation at BIOSPAIN 2026, underscoring the event’s growing international relevance. In this interview, Ceri Morgan, HM Trade Commissioner for Europe, shares the UK
-
NewGENESIS Biomed contributes to the development of growth strategies for KYMOS and other C...
ACCIÓ’s Noves Oportunitats de Negoci calls for proposals provide Catalan companies with a supportive framework for analysing and structuring new growth opportunities.
-
NewThe European Council advances the Biotech Act I legislative process
The EU EPSCO Council took a step forward in the legislative process of the Biotech Act I by agreeing on a common position regarding the proposed Directive, paving the way for negotiations with the
-
-
CompanyEURO-FUNDING
-
-
NewAseBio welcomes the European Parliament’s approval of New Genomic Techniques
For AseBio, the agreement marks a significant step towards a modern, science-based regulatory framework capable of fostering innovation and addressing key challenges such as climate change
-
NewWorld ALS Day | “ALS research is currently going through a particularly promising moment”
We interview Alfonso de Egaña Barrenechea, CEO of Molefy Pharma, a company developing AP-2, an innovative molecule designed to restore TDP-43 function and modify the course of the disease.
-
Press releaseResearch on the TDP-43 protein opens new therapeutic avenues for ALS
Biotechnology is driving new strategies to combat ALS, including research on the TDP-43 protein, a key target involved in the majority of cases of the disease. Molefy Pharma, an AseBio member company
-
New#VozBiotech | The industrial ownership of NGT-1 plants: a geostrategic challenge for Europ...
Rafael López, Head of Technology Transfer and Director of the PONS IP Office in Valencia.
-
NewAseBio is involved in three key European initiatives aimed at boosting biotechnology compe...
We have contributed to the Fraunhofer Institute’s technical questionnaire on the Biotech Act II, the European Commission’s public consultation on this forthcoming legislative initiative, and the
-
Press release
AseBio is involved in three key European initiatives aimed at boosting biotechnology compe...
We have contributed to the Fraunhofer Institute’s technical questionnaire on the Biotech Act II, the European Commission’s public consultation on this forthcoming legislative initiative, and the
-
NewThe University of Barcelona Science Park reaches a new investment record of €230 million ...
The University of Barcelona Parc Científic de Barcelona (PCB-UB) broke its investment record in 2025, with a total of €229.7 million raised by the companies in its ecosystem. Start-ups, spin-offs and
-
NewShilpa Biocare Invests in Gate2Brain to Advance G2B-002, an Innovative Brain Cancer Thera...
Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake in the company.
-
NewStablepharma and AFT Move to Expand Fridge-Free Vaccine Distribution Following Positive Cl...
Potential agreement follows positive clinical and stability data, supporting rollout in UK, Canada, Australia and New Zealand.
-
-
-
-
NewOriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health...
Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund.
-
NewJoan Martí: “Corporate culture is a critical factor in M&A and partnership processes”
Joan Martí is Director of Business Strategy at ACCIÓ, the Agency for Business Competitiveness of the Government of Catalonia, where he has accumulated 30 years of experience.
-
NewORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia ...
In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to
